Targetome最新文献

筛选

英文中文

Comparing the spatial transcriptomic difference of the protective effect between Panax notoginseng and Panax ginseng against acute stroke with Spatial-seq 2.0 利用spatial - seq2.0比较三七和人参对急性脑卒中保护作用的空间转录组差异

Targetome Pub Date : 2026-01-01 DOI: 10.48130/targetome-0026-0038

Guoqian Cui, Renjie Chen, Yining Hu, Qikun Zhao, Hudong Bao, Shujun Xu, Shiyan Qian, Wenbo Guo, Xiaohui Fan, Jie Liao

引用次数: 0

Combination of silybin and carvedilol synergistically alleviates liver fibrosis by inhibiting Wnt/β-catenin signaling 水飞蓟宾联合卡维地洛通过抑制Wnt/&lt；i>β</i&gt；-catenin信号通路协同缓解肝纤维化

Targetome Pub Date : 2025-01-01 DOI: 10.48130/targetome-0025-0009

An Chen, Xiaochai Zhu, Houzhe Jiang, Mingkun Gong, Shuang Cui, Guangji Wang, Hong Wang, Haiping Hao

{"title":"Combination of silybin and carvedilol synergistically alleviates liver fibrosis by inhibiting Wnt/β-catenin signaling","authors":"An Chen, Xiaochai Zhu, Houzhe Jiang, Mingkun Gong, Shuang Cui, Guangji Wang, Hong Wang, Haiping Hao","doi":"10.48130/targetome-0025-0009","DOIUrl":"https://doi.org/10.48130/targetome-0025-0009","url":null,"abstract":"Liver fibrosis is a chronic and multifactorial liver disease that usually involves long-term hepatic injury, and is triggered mainly by hepatic stellate cells (HSCs) activation. Due to the complexity of liver fibrosis pathophysiology, the efficacy of monotherapies is limited. To overcome this limitation, the development of combination regimens has emerged as a potentially powerful strategy for treating liver fibrosis. In this study, a combination regimen involving silybin, a natural compound widely used for various liver diseases, with powerful antifibrotic efficacy was identified. The effects of 397 FDA-approved drugs in combination with silybin were evaluated using the COL1A1 luciferase reporter. Among the pairs of drugs, silybin and carvedilol had the strongest synergistic inhibitory effect on HSC activation. This synergistic effect was further validated in primary hepatic stellate cells (pHSCs) <italic>in vitro</italic>, and in CCl4-treated mice <italic>in vivo</italic>. The ratio with the strongest synergistic and inhibitory effects was systemically evaluated to identify the optimal fixed-dose combination (50:1 for silybin and carvedilol <italic>in vivo</italic>). This combination regimen significantly inhibited CCl4-induced liver fibrosis in a dose-dependent manner. Mechanistically, combined silybin and carvedilol inhibited HSCs activation through synergistically suppressing Wnt4/<italic>β</italic>-catenin signaling. This study provides a clinically feasible combination regimen with powerful synergistic and inhibitory effects on liver fibrosis.","PeriodicalId":522880,"journal":{"name":"Targetome","volume":"1 1","pages":"0-0"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147905317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1